© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
December 01, 2022
With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.
Individuals who had COVID-19 were 55% more likely to develop epilepsy or seizures over the following 6 months than those who had influenza.
November 29, 2022
Research into how perivascular spaces contribute to migraine could help better understand the complexities of how these headaches occur.
November 21, 2022
Research also focuses on connection between oral hygiene and other chronic diseases, neurological disorders, pulmonary infections.
November 14, 2022
Zilucoplan is a subcutaneous, self-administered peptide inhibitor of complement component 5.
November 10, 2022
Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.
November 07, 2022
A session presenter at the ASCP 2022 Annual Meeting explained how patients’ mismanagement of medications for headaches can lead to rebound headaches.
November 03, 2022
Eisai plans to file for traditional approval in the United States by March 31, 2023.
October 27, 2022
Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.
October 25, 2022
In patients with hypoxic-ischemic brain injury, researchers observed no significant difference between liberal and restrictive oxygenation on any-cause death.